Recent research indicates zinc plays a far more complex role in cardiovascular health than previously understood, extending beyond its well-known immune-supportive functions. A review published in the journal Metallomics synthesizes evidence suggesting zinc deficiency may be a significant, modifiable risk factor for inflammatory heart conditions like myocarditis and pericarditis.
The review, published February 29, 2026, examined the biochemical, therapeutic and immunological effects of zinc, concluding that maintaining optimal levels could bolster cardiovascular resilience. Researchers found zinc acts as both an antioxidant cofactor and a signaling molecule, modulating inflammatory cytokine signaling and oxidative stress pathways implicated in heart tissue damage. However, the authors emphasize that much of the supporting evidence remains preclinical or mechanistic, and large-scale randomized controlled trials are needed.
While the human body contains only approximately 2 grams of zinc, the trace element is crucial for immune regulation, wound healing, and DNA synthesis, according to the review. Inflammatory heart conditions, particularly myocarditis and pericarditis, have garnered increased clinical attention in recent years, sometimes leading to sudden cardiac death, especially in young adults and athletes. These conditions are often triggered by viral infections, including SARS-CoV-2, or autoimmune responses.
The review highlights a biological mechanism termed the “Redox Zinc Switch,” where zinc is released from proteins during cellular stress. This released zinc then functions as a secondary messenger, activating protective signaling pathways – specifically protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) – to preserve heart tissue. However, this protective mechanism falters in zinc-deficient conditions, leading to cell death and cardiac remodeling.
Zinc’s protective function is attributed to its ability to inhibit Nuclear Factor kappa B (NF-κB), a protein complex that controls DNA transcription and cell survival. Under normal conditions, NF-κB is inactive, but during infection, it triggers the release of pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Zinc promotes the expression of A20, a protein that halts the NF-κB signaling pathway. Studies using HL-60 cell lines demonstrated that zinc supplementation significantly enhanced A20 activity, dampening the inflammatory response.
zinc is an essential cofactor for superoxide dismutase (Cu/Zn-SOD), an enzyme that neutralizes toxic superoxide radicals. The review also cites data showing zinc inhibits NADPH oxidase, an enzyme involved in the generation of reactive oxygen species (ROS), and boosts glutathione synthesis, a potent antioxidant.
A systematic review and meta-analysis, currently underway and registered as of October 7, 2025, aims to assess the relationship between blood concentrations of zinc and selenium and prognosis in post-acute myocardial infarction. Researchers at the Federal University of Rio Grande do Norte in Brazil are conducting the study, analyzing data to determine if zinc and selenium levels correlate with patient outcomes.
The Metallomics review suggests that future clinical strategies may need to utilize zinc ionophores – molecules that facilitate zinc transport into cells, such as quercetin – to ensure the mineral reaches cardiac tissue. The authors caution that current blood-based zinc biomarkers may not accurately reflect intracellular zinc status and that both deficiency and excessive supplementation can disrupt physiological homeostasis, requiring careful clinical consideration.
